» Articles » PMID: 33858765

Broadly Neutralizing Antibodies for HIV-1 Prevention and Therapy

Overview
Journal Semin Immunol
Date 2021 Apr 16
PMID 33858765
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Despite immense progress in our ability to prevent and treat HIV-1 infection, HIV-1 remains an incurable disease and a highly efficacious HIV-1 vaccine is not yet available. Additional tools to prevent and treat HIV-1 are therefore necessary. The identification of potent and broadly neutralizing antibodies (bNAbs) against HIV-1 has revolutionized the field and may prove clinically useful. Significant advances have been made in identifying broader and more potent antibodies, characterizing antibodies in preclinical animal models, engineering antibodies to extend half-life and expand breadth and functionality, and evaluating the efficacy of single bNAbs and bNAb combinations in people with and without HIV-1. Here, we review recent progress in developing bNAbs for the prevention and treatment of HIV-1.

Citing Articles

SHIV fights back to evade destruction by eCD4-Ig but not without suffering debilitating wounds.

Arts E Mol Ther. 2025; 33(2):427-429.

PMID: 39842428 PMC: 11852662. DOI: 10.1016/j.ymthe.2025.01.001.


HIV Vaccine Development at a Crossroads: New B and T Cell Approaches.

Govindan R, Stephenson K Vaccines (Basel). 2024; 12(9).

PMID: 39340073 PMC: 11435826. DOI: 10.3390/vaccines12091043.


Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial.

Julg B, Walker-Sperling V, Wagh K, Aid M, Stephenson K, Zash R Nat Med. 2024; 30(12):3534-3543.

PMID: 39266747 PMC: 11645281. DOI: 10.1038/s41591-024-03247-5.


Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens.

Williamson B, Wu L, Huang Y, Hudson A, B Gilbert P PLoS One. 2024; 19(9):e0310042.

PMID: 39240995 PMC: 11379218. DOI: 10.1371/journal.pone.0310042.


Macrophage- and CD4+ T cell-derived SIV differ in glycosylation, infectivity and neutralization sensitivity.

Karsten C, Buettner F, Cajic S, Nehlmeier I, Roshani B, Klippert A PLoS Pathog. 2024; 20(5):e1012190.

PMID: 38805549 PMC: 11161069. DOI: 10.1371/journal.ppat.1012190.